Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Faruk TasKayhan ErturkPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Single-agent temozolomide may be a rational and prudent option for late adjuvant therapy in melanoma patients if/when novel therapies, such as targeting and immune therapies, are not accessible or available.